Suven Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
For the nine months, sales was INR 93.08 million compared to INR 109.28 million a year ago. Revenue was INR 261.55 million compared to INR 137.75 million a year ago. Net loss was INR 785.36 million compared to INR 906.23 million a year ago. Basic loss per share from continuing operations was INR 3.6 compared to INR 5.46 a year ago. Diluted loss per share from continuing operations was INR 3.6 compared to INR 5.46 a year ago.